Point of Care Liquid Biopsy for Cancer Treatment—Early Experience from a Community Center
2024; Multidisciplinary Digital Publishing Institute; Volume: 16; Issue: 14 Linguagem: Inglês
10.3390/cancers16142505
ISSN2072-6694
AutoresC. J. Nicholas, Andrea Beharry, Anna Bendzsak, Kassandra R. Bisson, Keith Dadson, Shaan Dudani, Marco Iafolla, Kashif Irshad, Kirstin Perdrizet, William Raskin, Raviya Singh, David Chun Cheong Tsui, Xin Wang, Ching Yeung, Parneet Cheema, Brandon S. Sheffield,
Tópico(s)Evolution and Genetic Dynamics
ResumoLiquid biopsy is rapidly becoming an indispensable tool in the oncologist's arsenal; however, this technique remains elusive in a publicly funded healthcare system, and real-world evidence is needed to demonstrate utility and feasibility. Here, we describe the first experience of an in-house point of care liquid biopsy program at a Canadian community hospital. A retrospective review of consecutive cases that underwent plasma-based next-generation sequencing (NGS) was conducted. Liquid biopsy was initiated at the discretion of clinicians. Sequencing followed a point of care workflow using the Genexus™ integrated sequencer and the Oncomine precision assay, performed by histotechnologists. Results were reported by the attending pathologist. Eligible charts were reviewed for outcomes of interest, including the intent of the liquid biopsy, results of the liquid biopsy, and turnaround time from blood draw to results available. A total of 124 cases, with confirmed or suspected cancer, underwent liquid biopsy between January 2021 and November 2023. The median turnaround time for liquid biopsy results was 3 business days (range 1-12 days). The sensitivity of liquid biopsies was 71%, compared to tissue testing in cases with matched tissue results available for comparison. Common mutations included
Referência(s)